Status: Recruiting
Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria
This study is a multicentre, randomized, open-label, non-inferiority clinical trial. The purpose and aim of this study is to investigate if patients with well controlled (UCT score score ≥ 12) chronic spontaneous urticaria (CSU) on omalizumab 300 mg every four weeks can extend treatment intervals and maintain disease control.
Participants needed: 40
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Simon Francis ThomsenUpdated: Sep 19, 2025Locations: 1
Eligibility criteria
A diagnosis of CSU according to the EAACI/GA2LEN/EDF/WAO guidelines. [+4]
Pregnant or breastfeeding women. [+6]